Role of Notch 1 signaling in esophageal carcinogenesis

Notch 1信号在食管癌发生中的作用

• 批准号: 8827716
• 负责人: Kelly A Whelan
• 金额: $ 1.6万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8827716
• 关键词: 3-Dimensional; Biological Assay; Biology; CD44 gene; Cell Differentiation process; Cell Line; Cells; Characteristics; Data; Development; Diagnosis; Differentiation Antigens; Disease; Disease Progression; Engineering; Epithelial; Esophageal; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Foundations; Gene Targeting; Generations; Genetically Engineered Mouse; Health; Human; Hyaluronic Acid; Hyperplasia; Immunoprecipitation; In Vitro; Lesion; Maintenance; Malignant - descriptor; Malignant Epithelial Cell; Malignant Neoplasms; Mediating; Mesenchymal; Migration Assay; Molecular; Mus; Oncogenes; Pathway interactions; Patients; Population; Property; Publishing; Reporting; Research; Resistance; Role; Scientific Advances and Accomplishments; Signal Pathway; Signal Transduction; Skin; Squamous Cell; Squamous Differentiation; Squamous cell carcinoma; System; Testing; Transcriptional Regulation; Transforming Growth Factor beta; Transforming Growth Factors; Tumor Biology; Tumor Suppressor Proteins; Tumorigenicity; base; cancer cell; cancer type; carcinogenesis; chemoradiation; chromatin immunoprecipitation; in vivo; innovation; insight; keratinocyte; lentiviral-mediated; monolayer; mouse model; neoplastic cell; notch protein; novel; novel strategies; novel therapeutics; outcome forecast; overexpression; promoter; receptor; receptor-mediated signaling; response; self-renewal; targeted cancer therapy; therapy development; tumor; tumor growth; tumor initiation; tumor progression; tumor xenograft; tumorigenesis; tumorigenic

DESCRIPTION (provided by applicant): Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive forms of human squamous cell carcinoma (SCC). ESCC patient prognosis remains poor due to late diagnosis and limited response to chemoradiotherapy, highlighting the need for novel therapeutic strategies in the treatmen of this disease. Tumor-initiating cells (TICs) are subsets of tumor cells possessing self-renewal and differentiation capabilities as well as enhanced chemoresistance, properties that have contributed to their emergence as cancer therapy targets. TICs, defined by high expression of CD44, the receptor for hyaluronic acid, have been identified in ESCC~ however, mechanisms regulating these subpopulations have yet to be elucidated. We have isolated CD44 High (CD44H) populations displaying characteristics of TICs from ESCC cells and demonstrated that transforming growth factor (TGF)-beta, promotes expansion of CD44H subpopulations concomitant with activation of Notch signaling. The Notch pathway is a context-dependent regulator of cell fate that is dysregulated in diverse cancer types~ however, the role of this pathway in ESCC is not yet known. In the current proposal, we hypothesize that Notch (N1) activation in the invasive front of ESCC acts in concert with TGF-beta to facilitate expansion of CD44H cell populations that are associated with the malignant properties of ESCC. We will test this through three interrelated specific aims. Aim 1 is to elucidate the role of N1 in expansion of CD44H ESCC cell populations. This will be achieved using inducible lentiviral overexpression and silencing systems to determine the requirement for N1 signaling in generation of CD44H cells in monolayer and 3-dimensional culture. These expression systems will also be used in concert with assays of migration, invasion, colony formation and xenograft tumor formation to assess the role of N1 in CD44H cell- mediated tumorigenicity. Aim 2 is to characterize the molecular mechanisms through which N1 and TGF-ß cooperate to promote CD44H cell expansion. Based on published findings and preliminary data, we hypothesize that TGF-ß- and N1-mediated signaling pathways may crosstalk to initiate a cell fate switch involving suppression of the N1 target gene Notch 3 (N3). We will test this by examining the influence of TGF-ß on N1-mediated transcriptional regulation of N3 using immunoprecipitation (IP), promoter activity assays and chromatin IP. We will also use inducible lentiviral-mediated overexpression and silencing systems to investigate the role o N3 signaling in generation of CD44H subpopulations. Aim 3 is to characterize the role of N1 in tumor growth and TIC expansion in vivo using genetically engineered mouse models. We will evaluate the role of N1 in ESCC progression by inactivating N1 in established ESCC lesions using inducible K5-ERT-Cre~Notch1floxf/lox mice and assessing effects on tumor progression and TIC content. Collectively, these studies will reveal mechanisms through which N1 supports ESCC progression while building a platform for new avenues toward translational applications for therapy of ESCC, which remains resistant to existing therapies.

描述（由申请人提供）：食管鳞状细胞癌（ESCC）是最具侵袭性的人类鳞状细胞癌（SCC）之一。由于ESCC患者诊断较晚，对放化疗的反应有限，预后仍然很差，因此需要新的治疗策略来治疗这种疾病。肿瘤启动细胞（tic）是肿瘤细胞的一个子集，具有自我更新和分化能力，以及增强的化疗耐药性，这些特性使它们成为癌症治疗的靶点。由高表达CD44（透明质酸受体）定义的tic已在ESCC中被发现，但调节这些亚群的机制尚未阐明。我们从ESCC细胞中分离出具有tic特征的CD44 High （CD44H）群，并证明转化生长因子(TGF)- β促进CD44H亚群的扩增，同时激活Notch信号。Notch通路是一种环境依赖性的细胞命运调节因子，在多种癌症类型中失调，然而，该通路在ESCC中的作用尚不清楚。在目前的建议中，我们假设ESCC侵袭性前部的Notch （N1）激活与tgf - β协同作用以促进扩张